A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Trial details

Who runs it

Incyte Corporation

Trial code

NCT06804811EU 2024-513171-41-00

Record updated

9 October 2026

Original description

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.Read full original descriptionShow less

A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.

Inclusion: Aged 6 to < 12 years at the time of signing the ICF; Clinical diagnosis of nonsegmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI; Total body vitiligo area does not exceed 10% BSA; Pigmented hair within some of the areas of vitiligo on the face; Must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit; For sexually active participants (except participants who are prepubescent) willingness to avoid pregnancy or fathering a child as defined in the protocol.

Exclusion: Prior or current use of depigmentation treatments (eg, monobenzone); Concurrent conditions and history of protocol-defined diseases; Use of protocol-defined treatments within the indicated washout period before baseline; Other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor); Any other skin disease that, in the opinion of the investigator, would interfere with the study drug application or study assessments; Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; History of treatment failure with any systemic or topical JAK inhibitor for vitiligo or any other inflammatory condition; Known allergy or reaction to any component of the study cream formulation; Protocol-defined clinically significant abnormal laboratory values at screening; BMI-for-age < 5th percentile or ≥ 85th percentile according to the CDC BMI Percentile Calculator for Child and Teen; Diagnosis of other forms of vitiligo (eg, segmental); Pregnant or lactating participants or those considering pregnancy during the period of their study participation; In the opinion of the investigator, unable or unlikely to comply with the application schedule and study evaluations; Living with anyone participating in any current Incyte-sponsored ruxolitinib cream study; Employees of the sponsor or investigator or are otherwise dependents of them; The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health code; In the EU, participants considered incapacitated according to EU CTR No. 536/2014 Articles 2 and 31; Other protocol-defined Inclusion/Exclusion Criteria may apply.

ClinicalTrials.gov NCT06804811 · EU CTIS 2024-513171-41-00